Browse by Phase
Phase 3 Clinical Trials
Phase 3 trials compare a new drug or treatment against the current standard of care in a large population (300–3,000+ participants). Successful Phase 3 results are the basis for regulatory approval.
Total Trials
498
Recruiting Now
498
Top Conditions in Phase 3
Frequently Asked Questions — Phase 3 Trials
Why are Phase 3 trials the standard for drug approval?
Phase 3 trials compare a new treatment against the current standard of care in a large, randomized population of 300–3,000+ participants. This large-scale comparative evidence is what regulatory agencies—FDA, EMA—require to approve a new drug. A successful Phase 3 trial demonstrates that the new treatment is more effective, safer, or both compared to existing options in a statistically significant, reproducible way.
What is a placebo control in a Phase 3 trial?
Many Phase 3 trials use a placebo control—a group that receives an inactive substance—to isolate the true effect of the treatment. When an established standard of care exists, control-arm participants typically receive that treatment rather than a placebo, for ethical reasons. Blinded designs prevent participants and investigators from knowing who received which treatment, reducing bias in outcome assessment.
How do I find and join a Phase 3 clinical trial?
ClinicalMetric lists all Phase 3 trials registered on ClinicalTrials.gov. Each trial card shows recruitment status, enrollment target, sponsor, conditions studied, and site locations. To join a Phase 3 trial, review the eligibility criteria and contact the trial site directly—usually an academic medical center or hospital. Your physician can facilitate a referral to the appropriate study site.
Active Phase 3 Studies
NCT05481723 Phase 3
Recruiting
Lung Ultrasound-guided Hemodynamic Optimization
Condition
Lung Ultrasound
Enrollment
350 pts
Location
France
Sponsor
Centre Hospitalier Universitai
NCT05946213 Phase 3
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in...
Condition
Prostate Adenocarcinoma
Enrollment
1,209 pts
Location
United States, Canada, Hong Kong
Sponsor
NRG Oncology
NCT05577988 Phase 3
Recruiting
Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therap...
Condition
MYOCARDIAL INFARCTION
Enrollment
2,468 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux
NCT07515079 Phase 3
Recruiting
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Mac...
Condition
Diabetic Macular Edema (DME)
Enrollment
406 pts
Location
China
Sponsor
Bio-Thera Solutions
NCT06419946 Phase 3
Recruiting
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Gliob...
Condition
Glioblastoma, IDH-wildtype
Enrollment
200 pts
Location
Austria, Denmark, Norway
Sponsor
Vastra Gotaland Region
NCT07623668 Phase 3
Recruiting
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
Condition
Optic Neuritis
Enrollment
210 pts
Location
United States
Sponsor
Oculis
NCT07379190 Phase 3
Recruiting
HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)
Condition
Stroke, Acute
Enrollment
458 pts
Location
China
Sponsor
Weifang Medical University
NCT07158242 Phase 3
Recruiting
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7...
Condition
Moderately to Severely Active Ulcerative Colitis
Enrollment
100 pts
Location
United States, Australia, Brazil
Sponsor
Hoffmann-La Roche
NCT07064486 Phase 3
Recruiting
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
Condition
Type 2 Diabetes (T2DM)
Enrollment
477 pts
Location
Indonesia
Sponsor
BrightGene Bio-Medical Technol
NCT07047092 Phase 3
Recruiting
Non-invasive Ventilation or CPAP in OSA-COPD Following Admission for an Acute Hy...
Condition
Chronic Obstructive Pulmonary Disease Exacerbation
Enrollment
386 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux
NCT06779136 Phase 3
Recruiting
Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prur...
Condition
Prurigo Nodularis
Enrollment
160 pts
Location
China
Sponsor
Shanghai Mabgeek Biotech.Co.Lt
NCT06071637 Phase 3
Recruiting
Low Power Laser Therapy As Prevention Of Oral Mucositis And Oropharyngeal Pain I...
Condition
Hematopoietic Stem Cell Transplantation
Enrollment
84 pts
Location
Brazil
Sponsor
Instituto Nacional de Cancer,
NCT06492395 Phase 3
Recruiting
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC Wit...
Condition
Hepatocellular Carcinoma Non-resectable
Enrollment
178 pts
Location
China
Sponsor
Second Affiliated Hospital of
NCT05609630 Phase 3
Recruiting
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate ...
Condition
Juvenile Idiopathic Arthritis
Enrollment
90 pts
Location
United States, Argentina, Australia
Sponsor
AbbVie
NCT05415267 Phase 3
Recruiting
Immunosuppression and COVID-19 Boosters
Condition
COVID-19
Enrollment
320 pts
Location
Australia
Sponsor
Kirby Institute
NCT05261139 Phase 3
Recruiting
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatr...
Condition
COVID-19
Enrollment
160 pts
Location
United States, Bulgaria, Japan
Sponsor
Pfizer
NCT07113275 Phase 3
Recruiting
A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed...
Condition
Rectal Cancer
Enrollment
444 pts
Location
China
Sponsor
Tao Zhang
NCT07361302 Phase 3
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke Whe...
Condition
Acute Ischemic Stroke
Enrollment
1,325 pts
Location
Argentina, Australia, Bulgaria
Sponsor
Boehringer Ingelheim
NCT05331937 Phase 3
Recruiting
TMS for Exposure Therapy Resistant OCD
Condition
1 Hz Real rTMS to the Pre-SMA
Enrollment
250 pts
Location
Netherlands
Sponsor
Amsterdam UMC, location VUmc
NCT07566156 Phase 3
Recruiting
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradioth...
Condition
Urothelial Cancer
Enrollment
390 pts
Location
United States, Canada
Sponsor
Astellas Pharma Global Develop
NCT07084519 Phase 3
Recruiting
Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction
Condition
Breast Cancer
Enrollment
506 pts
Location
China
Sponsor
Cancer Institute and Hospital,
NCT06300177 Phase 3
Recruiting
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally...
Condition
Non Small Cell Lung Cancer
Enrollment
522 pts
Location
China
Sponsor
Chia Tai Tianqing Pharmaceutic
NCT07264075 Phase 3
Recruiting
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab...
Condition
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Enrollment
780 pts
Location
France
Sponsor
Groupe Oncologie Radiotherapie
NCT07544030 Phase 3
Recruiting
A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficac...
Condition
Ovarian Cancer
Enrollment
60 pts
Location
China
Sponsor
tongweihua
NCT07237256 Phase 3
Recruiting
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer...
Condition
Breast Cancer
Enrollment
3,902 pts
Location
France, Germany, Italy
Sponsor
UNICANCER
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology